Tuesday – Virility Medical, an Israeli startup, has announced the upcoming launch of its innovative medical device, in2, designed to treat premature ejaculation (PE) in Israel. Following a successful introduction in the UK, the company aims to address the most common male sexual health concern with this drug-free solution.
The in2 device offers an immediate effect with no adverse side effects or pain, making it a revolutionary option for men dealing with PE. The device has undergone rigorous clinical testing, demonstrating its ability to extend the duration of sexual intercourse and enhance orgasm. Virility Medical has secured full regulatory approval, including FDA clearance for the U.S. market, CE approval for Europe, and approval from the Israeli Ministry of Health.
Premature ejaculation affects approximately 25% of men worldwide, with the treatment industry valued at $2.4 billion. Virility Medical, founded in 2016 in Hod Hasharon by a team of scientists and urologists, focuses on EMS (Electrical Muscle Stimulation) technology research and the development of treatments for PE.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
CEO Sharon Ravid highlighted the significance of the in2 device, stating, “This is groundbreaking news for millions of men experiencing the common phenomenon of premature ejaculation. Current solutions on the market often come with numerous side effects, prolonged waiting times, and a lack of spontaneity during sexual relations. Our device offers an easy and effective solution, free from side effects and drugs, with an immediate effect.”
Ravid further emphasized Virility Medical’s collaborative efforts: “At Virility Medical, we actively collaborate with specialist doctors, sexual therapists, and opinion leaders in the sexual health field.”
The in2 device, tailored specifically for male anatomy, uses EMS technology to stimulate and contract pelvic muscles, enhancing the body’s natural ability to delay ejaculation. It is thin, non-addictive, non-invasive, and free from chemicals and drugs, allowing for immediate use without any waiting time before sexual intercourse.
Supporting the efficacy of EMS technology, a 2018 Brazilian study demonstrated significant improvement in PE symptoms for those who received EMS treatment. This evidence underpins the potential of the in2 device to provide a substantial improvement in the quality of life for men dealing with PE.
As Virility Medical prepares to introduce in2 to the Israeli market, the company is poised to offer a solution that not only addresses a widespread issue but also improves intimacy between couples. The launch marks a significant milestone in the field of male sexual health, providing a novel, effective, and side-effect-free option for those affected by premature ejaculation.
